Functional nodules in primary aldosteronism: identification of CXCR4 expression with Ga-pentixafor PET/CT
Creators
- 1. NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Dongcheng, 100730, Beijing (China)
- 2. Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine and State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, 100730, Beijing (China)
- 3. Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 100730, Beijing (China)
- 4. Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 100730, Beijing (China)
- 5. Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 100730, Beijing (China)
Description
We analyzed the diagnostic efficiency of Ga-pentixafor PET/CT for functional nodules in primary aldosteronism (PA). Furthermore, we compared the correlation of CXCR4 expression with aldosterone synthase (CYP11B2) expression and PET/CT uptake in these patients. We prospectively assessed 50 patients diagnosed with PA and 10 patients with non-functional adrenal adenoma (NFA). All patients underwent Ga-pentixafor PET/CT before adrenalectomy. Immunohistochemistry (IHC) was performed to detect the protein expression of CYP11B2 and the G-protein-coupled receptor CXCR4. CYP11B2 IHC revealed the presence of 43 functional nodules. Subsequently, 40/43 functional nodules could be detected on Ga-pentixafor PET/CT, while negative imaging findings were noted for 11/13 non-functional nodules (sensitivity, 93.0%; specificity, 84.6%). The optimum SUV cut-off for the identification of functional nodules was 8.95 (AUC 0.914 [0.828-1.000], p < 0.001). Regarding the size of functional nodules, diagnostic efficiency appeared to be much higher for nodules greater than 1 cm in size (sensitivity, up to 97.3%). Moreover, we examined the relationship between CXCR4 and CYP11B2 expression in 56 lesions. All 43 CYP11B2-positive nodules were CXCR4-positive, but one of the 13 CYP11B2-negative nodules (7.7%) showed false-positive staining for CXCR4. Moreover, the consistency between PET/CT uptake and CXCR4 staining results was 92.9% (52/56). At least 90% of functional nodules show positive uptake on Ga-pentixafor PET/CT, and the detection ability is much better for nodules with a diameter ≥ 1 cm. With its high sensitivity and specificity, Ga-pentixafor PET/CT can be considered a promising surgical decision-making tool for patients with PA. Ga-pentixafor PET/CT could be a useful tool for the identification of functional adrenal nodules in APAs and even IHAs. The diagnostic efficiency appears to be much higher for nodules ≥ 1 cm in size. There is high consistency between the results of 68Ga-pentixafor PET/CT imaging and CXCR4 immunohistochemistry.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00330-022-09058-xAdditional details
Identifiers
Publishing Information
- Journal Title
- European Radiology (Internet)
- Journal Volume
- 33
- Journal Issue
- 2
- Journal Page Range
- p. 996-1003
- ISSN
- 1432-1084
- CODEN
- EURAE3
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 54030613
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ADENOMAS; ADRENALECTOMY; ALDOSTERONE; COMPARATIVE EVALUATIONS; CORRELATIONS; CYTOCHROMES; DECISION MAKING; DIAGNOSIS; EFFICIENCY; GALLIUM 68; GTP-ASES; POSITRON COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS; SENSITIVITY; SIZE; SPECIFICITY; UPTAKE
- Descriptors DEC
- ACID ANHYDRASES; ADRENAL HORMONES; ALDEHYDES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; CARCINOMAS; COMPUTERIZED TOMOGRAPHY; CORTICOSTEROIDS; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; EMISSION COMPUTED TOMOGRAPHY; ENZYMES; EVALUATION; GALLIUM ISOTOPES; HORMONES; HOURS LIVING RADIOISOTOPES; HYDROLASES; HYDROXY COMPOUNDS; INTERMEDIATE MASS NUCLEI; ISOTOPES; KETONES; LABELLED COMPOUNDS; MATERIALS; MEDICINE; MEMBRANE PROTEINS; MINERALOCORTICOIDS; NEOPLASMS; NUCLEI; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; PIGMENTS; PREGNANES; PROTEINS; RADIOACTIVE MATERIALS; RADIOISOTOPES; STEROID HORMONES; STEROIDS; SURGERY; TOMOGRAPHY